Patents by Inventor Eileen Geoghegan

Eileen Geoghegan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230390424
    Abstract: Compositions and methods for treating a solid cancer in a subject by administering an effective amount of a radioisotope labeled trophoblast glycoprotein (5T4)-targeting agent are provided. The 5T4-targeting agent may be an antibody against 5T4 labeled with 225Ac, 177Lu, 131I, 90Y, 213Bi, 211At, 212Bi, 227Th, or 212Pb. The solid cancer may be a 5T4-positive tumor. The effective amount of the radiolabeled 5T4-targeting agent may be a maximum tolerate dose administered in a single bolus or in fractionated doses that together equal the maximum tolerated dose. The methods may further include administration of additional agents, such as chemotherapeutic agents, immune checkpoint therapies, and/or DNA damage response inhibitors.
    Type: Application
    Filed: September 13, 2021
    Publication date: December 7, 2023
    Inventors: Dale L. LUDWIG, Eileen GEOGHEGAN
  • Publication number: 20230302168
    Abstract: Methods for treating a proliferative disease or disorder by administering an antibody radio-conjugate alone or in combination with an immune checkpoint therapy such as an antibody against an immune checkpoint inhibitor, and/or a DNA damage response inhibitor. The proliferative disease or disorder may be a solid cancer, such as breast cancer, ovarian cancer, or prostate cancer.
    Type: Application
    Filed: June 23, 2021
    Publication date: September 28, 2023
    Inventors: Dale LUDWIG, Eileen GEOGHEGAN
  • Publication number: 20230248855
    Abstract: Provided are compositions and methods for treating a solid cancer such as a HER3-positive tumor in a subject by administering an effective amount of a HER3-targeting agent labeled with a radionuclide such as 225Ac, 177Lu, 131I, 90Y, 213Bi, 211At, 213Bi, 227Th, or 212Pb, alone or in combination with other therapeutic agents or modalities such as VEGF or VEGFR inhibitors. The effective amount of the radiolabeled HER3-targeting agent may be a maximum tolerated dose administered in a single bolus or in fractionated doses that together equal the maximum tolerated dose.
    Type: Application
    Filed: December 23, 2022
    Publication date: August 10, 2023
    Inventors: DALE L LUDWIG, Eileen Geoghegan, Sandesh Seth, Paul Diamond
  • Publication number: 20220202967
    Abstract: Compositions and methods for transient immunodepletion of specific subsets of a subject's immune cells are disclosed. The methods generally include administering to the subject an effective amount of a radiolabeled antibody against CD19, CD20, CD33, CD38, CD45RA, CD52, or a combination thereof. The effective amount of the radiolabeled antibody depletes at least 50% of the targeted immune cells, and less than 20% of the subject's stem cells. When used alone, these methods may target lymphomas, leukemias, and myelomas, and/or may additionally allow repopulation of non-autoreactive immune cells in patients with an autoimmune disease. When these methods precede certain cell-based therapies, such as adoptive cell therapy and/or hematopoietic stem cell therapy, the methods are able to enhance the outcome of the cell-based therapies while minimizing adverse effects.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 30, 2022
    Applicant: ACTINIUM PHARMACEUTICALS, INC.
    Inventors: Dale Ludwig, Eileen Geoghegan
  • Publication number: 20220143228
    Abstract: Provided are compositions and methods for treating a solid cancer such as a HER3-positive tumor in a subject by administering an effective amount of a HER3-targeting agent labeled with a radionuclide such as 225Ac, 177Lu, 131I, 90Y, 213Bi, 211At, 213Bi, 227Th, or 212Pb, alone or in combination with other therapeutic agents or modalities. The effective amount of the radiolabeled HER3-targeting agent may be a maximum tolerate dose administered in a single bolus or in fractionated doses that together equal the maximum tolerated dose.
    Type: Application
    Filed: November 22, 2021
    Publication date: May 12, 2022
    Inventors: Dale L Ludwig, Eileen Geoghegan, Sandesh Seth, Paul Diamond
  • Patent number: 10376596
    Abstract: The present invention provides heavy chain immunoglobulins of the VHH type or fragment thereof having affinity for a target antigen of interest, including glycoprotein D2 (gD2) of HSV-2 or antigen thereof, and for envelope proteins of HIV-1 or an antigen thereof linked to Pseudomonas exotoxin A or functional fragments thereof. Also included are multimeric forms of the immunoglobulins and their use in the prevention and/or treatment of HSV2 and/or HIV-1.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: August 13, 2019
    Assignee: The Johns Hopkins University
    Inventors: Richard Markham, Eileen Geoghegan
  • Publication number: 20180289833
    Abstract: The present invention provides heavy chain immunoglobulins of the VHH type or fragment thereof having affinity for a target antigen of interest, including glycoprotein D2 (gD2) of HSV-2 or antigen thereof, and for envelope proteins of HIV-1 or an antigen thereof linked to Pseudomonas exotoxin A or functional fragments thereof. Also included are multimeric forms of the immunoglobulins and their use in the prevention and/or treatment of HSV2 and/or HIV-1.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 11, 2018
    Inventors: Richard Markham, Eileen Geoghegan
  • Patent number: 10010625
    Abstract: The present invention provides heavy chain immunoglobulins of the VHH type or fragment thereof having affinity for a target antigen of interest, including glycoprotein D2 (gD2) of HSV-2 or antigen thereof, and for envelope proteins of HIV-1 or an antigen thereof linked to Pseudomonas exotoxin A or functional fragments thereof. Also included are multimeric forms of the immunoglobulins and their use in the prevention and/or treatment of HSV2 and/or HIV-1.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: July 3, 2018
    Assignee: The Johns Hopkins University
    Inventors: Richard Markham, Eileen Geoghegan
  • Publication number: 20160339112
    Abstract: The present invention provides heavy chain immunoglobulins of the VHH type or fragment thereof having affinity for a target antigen of interest, including glycoprotein D2 (gD2) of HSV-2 or antigen thereof, and for envelope proteins of HIV-1 or an antigen thereof linked to Pseudomonas exotoxin A or functional fragments thereof. Also included are multimeric forms of the immunoglobulins and their use in the prevention and/or treatment of HSV2 and/or HIV-1.
    Type: Application
    Filed: January 2, 2015
    Publication date: November 24, 2016
    Inventors: Richard Markham, Eileen Geoghegan